CO2021014918A2 - Proteínas de unión triespecíficas, métodos y usos de las mismas - Google Patents

Proteínas de unión triespecíficas, métodos y usos de las mismas

Info

Publication number
CO2021014918A2
CO2021014918A2 CONC2021/0014918A CO2021014918A CO2021014918A2 CO 2021014918 A2 CO2021014918 A2 CO 2021014918A2 CO 2021014918 A CO2021014918 A CO 2021014918A CO 2021014918 A2 CO2021014918 A2 CO 2021014918A2
Authority
CO
Colombia
Prior art keywords
binding
binding proteins
trivalent
polypeptide
proteins
Prior art date
Application number
CONC2021/0014918A
Other languages
English (en)
Inventor
Tarik Dabdoubi
Béatrice Cameron
Cendrine Lemoine
Catherine Prades
Zhi-Yong Yang
Joerg Birkenfeld
Gary J Nabel
Huawei Qiu
Joerg Regula
Edward Seung
Ronnie Wei
Lan Wu
Zhen Xing
Ling Xu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2021014918A2 publication Critical patent/CO2021014918A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente memoria se proporcionan proteínas de unión triespecíficas y/o trivalentes que comprenden cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas diana, en donde un primer par de polipéptidos que forma la proteína de unión posee dominios variables dobles que tienen una orientación cruzada, y en donde un segundo par de polipéptidos posee un dominio variable único que forma un único sitio de unión a antígeno. En algunas modalidades, las proteínas de unión comprenden un sitio de unión que se une a un polipéptido CD28, un sitio de unión que se une a un polipéptido CD3, y un sitio de unión que se une a un tercer polipéptido, tal como una proteína diana tumoral. La divulgación también se refiere a métodos para elaborar proteínas de unión triespecíficas y/o trivalentes y a los usos de tales proteínas de unión.
CONC2021/0014918A 2019-04-09 2021-11-04 Proteínas de unión triespecíficas, métodos y usos de las mismas CO2021014918A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
CO2021014918A2 true CO2021014918A2 (es) 2021-11-19

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014918A CO2021014918A2 (es) 2019-04-09 2021-11-04 Proteínas de unión triespecíficas, métodos y usos de las mismas

Country Status (13)

Country Link
EP (1) EP3953388A1 (es)
JP (1) JP2022527994A (es)
KR (1) KR20210149141A (es)
CN (1) CN113950484A (es)
AU (1) AU2020272839A1 (es)
BR (1) BR112021019915A2 (es)
CA (1) CA3136821A1 (es)
CO (1) CO2021014918A2 (es)
IL (1) IL286929A (es)
MX (1) MX2021012386A (es)
SG (1) SG11202111012QA (es)
TW (1) TW202104261A (es)
WO (1) WO2020210392A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077118A2 (en) * 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) * 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2808914T3 (es) * 2014-09-04 2021-03-02 Stemcell Tech Inc Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
BR112017014805A2 (pt) * 2015-01-23 2018-01-09 Sanofi anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123
JP2018524312A (ja) * 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
WO2018120842A1 (zh) * 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 一种双功能分子及其应用
EA201892312A1 (ru) 2017-03-17 2019-04-30 Санофи Триспецифические и/или тривалентные связывающие белки
CN117964758A (zh) * 2017-10-10 2024-05-03 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
BR112021006558A2 (pt) * 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral

Also Published As

Publication number Publication date
EP3953388A1 (en) 2022-02-16
CN113950484A (zh) 2022-01-18
AU2020272839A1 (en) 2021-12-02
WO2020210392A1 (en) 2020-10-15
JP2022527994A (ja) 2022-06-07
BR112021019915A2 (pt) 2021-12-07
TW202104261A (zh) 2021-02-01
CA3136821A1 (en) 2020-10-15
KR20210149141A (ko) 2021-12-08
IL286929A (en) 2021-10-31
SG11202111012QA (en) 2021-11-29
MX2021012386A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
CO2018012107A2 (es) Proteínas de unión triespecíficas y/o trivalentes
CO2018005337A2 (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
PE20170767A1 (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos
AR124511A2 (es) Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
MX2020004129A (es) Anticuerpos anti-cd38 y metodos de uso.
MA39266A (fr) Anticorps bispécifiques anti cd3epsilon et bcma
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
EA201890337A1 (ru) Конструкции антитела к flt3 и cd3
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
BR112019005292A2 (pt) anticorpos para siglec-15 e métodos de uso dos mesmos.
GT201200253A (es) Proteínas terapéuticas de unión a dll4
TR201902400T4 (tr) Multivalan antijen bağlama Fv molekülü.
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
AR101753A1 (es) COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CO2021014918A2 (es) Proteínas de unión triespecíficas, métodos y usos de las mismas
ECSP13012996A (es) Moléculas de unión biespecíficas que se unen a dll4 y ang2.
EP4257193A3 (en) Trispecific and/or trivalent binding proteins
ECSP18084491A (es) Proteínas de unión triespecíficas y/o trivalentes
ECSP18039758A (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
AR118602A1 (es) Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih
AR108210A1 (es) Proteínas de unión triespecíficas y/o trivalentes
CO2022000404A2 (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden
EA202191187A1 (ru) Антитела к ctla4, фрагменты антител, их иммуноконъюгаты и их применение